{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T01:55:34Z","timestamp":1768528534037,"version":"3.49.0"},"posted":{"date-parts":[[2025,10,21]]},"group-title":"Biochemistry","reference-count":22,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"funder":[{"name":"National Institutes of Health, Institute on Drug Abuse Grant","award":["U01DA050330"],"award-info":[{"award-number":["U01DA050330"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,10,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>A humanized anti-cocaine mAb (h2E2) under development for the treatment of cocaine use disorders was deglycosylated enzymatically, and analyzed by differential scanning fluorimetry (DSF) using two distinct extrinsic dyes, and by FITC fluorescent labeling, to assess domain stability changes induced by deglycosylation of the Fc domain. The deglycosylated Fc fragment of the mAb was generated by proteolysis, and purified by ion exchange. Deglycosylation caused thermal destabilization of the glycosylated domain of the mAb, but there was no change in antigen (cocaine) binding or affinity. FITC fluorescent labeling of the deglycosylated mAb was suitable for qualitative assessment of cocaine binding. The thermal destabilization of the deglycosylated Fc fragment could be assessed by FITC labeling-based DSF, unlike the FITC-labeled control Fc fragment. This difference is due to the exposure of a secondary limited proteolysis site on the deglycosylated Fc, which increased accessibility and fluorescence labeling of Fc fragment lysine residues. Many of the methods and results in this study may be generalizable to numerous therapeutic mAbs, since the IgG1 anti-cocaine mAb shares the same glycosylation site and fully human heavy chain Fc sequence with other therapeutic human and humanized mAbs.<\/jats:p>","DOI":"10.1101\/2025.10.21.683661","type":"posted-content","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:30:10Z","timestamp":1761103810000},"source":"Crossref","is-referenced-by-count":0,"title":["Characterization of deglycosylated anti-cocaine mAb by differential scanning fluorimetry and fluorescence labeling"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6211-1414","authenticated-orcid":false,"given":"Terence L.","family":"Kirley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2025102408150442000_2025.10.21.683661v1.1","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.bbrc.2017.04.117","article-title":"Characterization of a recombinant humanized anti-cocaine monoclonal antibody produced from multiple clones for the selection of a master cell bank candidate","volume":"487","year":"2017","journal-title":"Biochemical and biophysical research communications"},{"key":"2025102408150442000_2025.10.21.683661v1.2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.drugalcdep.2016.09.024","article-title":"The effects of a repeated dose of a recombinant humanized anti-cocaine monoclonal antibody on cocaine self-administration in rats","volume":"168","year":"2016","journal-title":"Drug and alcohol dependence"},{"key":"2025102408150442000_2025.10.21.683661v1.3","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1124\/dmd.114.057034","article-title":"A recombinant humanized anti-cocaine monoclonal antibody inhibits the distribution of cocaine to the brain in rats","volume":"42","year":"2014","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"},{"key":"2025102408150442000_2025.10.21.683661v1.4","doi-asserted-by":"crossref","first-page":"101520","DOI":"10.1016\/j.bbrep.2023.101520","article-title":"Characterization and optimization of fluorescein isothiocyanate labeling of humanized h2E2 anti-cocaine mAb","volume":"35","year":"2023","journal-title":"Biochemistry and biophysics reports"},{"key":"2025102408150442000_2025.10.21.683661v1.5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.bbrc.2016.06.099","article-title":"Structural characterization of expressed monoclonal antibodies by single sample mass spectral analysis after IdeS proteolysis","volume":"477","year":"2016","journal-title":"Biochemical and biophysical research communications"},{"key":"2025102408150442000_2025.10.21.683661v1.6","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24444"},{"key":"2025102408150442000_2025.10.21.683661v1.7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejpb.2016.01.005","article-title":"N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins","volume":"100","year":"2016","journal-title":"European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V"},{"key":"2025102408150442000_2025.10.21.683661v1.8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/biot.201000091","article-title":"Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies","volume":"6","year":"2011","journal-title":"Biotechnology journal"},{"key":"2025102408150442000_2025.10.21.683661v1.9","unstructured":"T.S. Raju , Glycosylation variations with expression systems and their impact on biological activity of therapeutic immunoglobulins, BioProcess International, April (2003) 44\u201353."},{"key":"2025102408150442000_2025.10.21.683661v1.10","doi-asserted-by":"publisher","DOI":"10.1021\/bi00338a028"},{"key":"2025102408150442000_2025.10.21.683661v1.11","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23730"},{"key":"2025102408150442000_2025.10.21.683661v1.12","doi-asserted-by":"crossref","first-page":"112676","DOI":"10.1016\/j.jim.2019.112676","article-title":"A novel differential scanning fluorimetry analysis of a humanized anti-cocaine mAb and its ligand binding characteristics","volume":"476","year":"2020","journal-title":"J Immunol Methods"},{"key":"2025102408150442000_2025.10.21.683661v1.13","doi-asserted-by":"publisher","DOI":"10.1038\/227680a0"},{"key":"2025102408150442000_2025.10.21.683661v1.14","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/21645515.2014.990856","article-title":"Characterization of a recombinant humanized anti-cocaine monoclonal antibody and its Fab fragment","volume":"11","year":"2015","journal-title":"Human vaccines & immunotherapeutics"},{"key":"2025102408150442000_2025.10.21.683661v1.15","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1080\/19420862.2018.1551044","article-title":"Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms","volume":"11","year":"2019","journal-title":"mAbs"},{"key":"2025102408150442000_2025.10.21.683661v1.16","doi-asserted-by":"publisher","DOI":"10.1021\/bi5002163"},{"key":"2025102408150442000_2025.10.21.683661v1.17","doi-asserted-by":"publisher","DOI":"10.1177\/1087057114557781"},{"key":"2025102408150442000_2025.10.21.683661v1.18","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23633"},{"key":"2025102408150442000_2025.10.21.683661v1.19","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1021\/mp400666b","article-title":"Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies","volume":"12","year":"2015","journal-title":"Molecular pharmaceutics"},{"key":"2025102408150442000_2025.10.21.683661v1.20","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-009-0020-2"},{"key":"2025102408150442000_2025.10.21.683661v1.21","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-007-9516-9"},{"key":"2025102408150442000_2025.10.21.683661v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/bs.mie.2018.09.015"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.10.21.683661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:51:49Z","timestamp":1768470709000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2025.10.21.683661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":22,"URL":"https:\/\/doi.org\/10.1101\/2025.10.21.683661","relation":{},"subject":[],"published":{"date-parts":[[2025,10,21]]},"subtype":"preprint"}}